Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-134233 · Präparat HOS-097542
16 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended. The (90 mg/400 mg q.d.) + AUC: ↔ increased exposure of tenofovir could potentiate Emtricitabine/Rilpivirine/ Cmax: ↔ adverse reactions associated with tenofovir Tenofovir disoproxil Cmin: ↔ disoproxil, including renal disorders. (200 mg/25 mg/245 mg q.d.) Sofosbuvir: Renal function should be closely monitored AUC: ↔ (see section 4.4). Cmax: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) tenofovir disoproxil (HOS-108843) rilpivirine (HOS-088090)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage a7b1e37629f1ebf41fa7d3dc725d883dba9819a065ef576df81a548acbae8577 · Zeichen 19765–20990 im Abschnitt